Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
Jean‐Jacques Kiladjian(Délégation Paris 5), Bruno Cassinat(Inserm), Juliette Soret(Assistance Publique – Hôpitaux de Paris), Jean‐Christophe Ianotto(Inserm), Cendrine Chaffaut(Assistance Publique – Hôpitaux de Paris), Matthieu Resche‐Rigon(Inserm), Valérie Rolland‐Neyret(Centre Hospitalier Universitaire de Grenoble), Viviane Dubruille(Centre Hospitalier Universitaire de Nantes), Fiorenza Barraco(Hôpital Lyon Sud), Zineb Ghrieb(Inserm), Sylvie Chevret(Saint Louis University Hospital), Véronique Meignin(Saint Louis University Hospital), Nabih Maslah(Memorial Sloan Kettering Cancer Center), Amandine Tisserand(Inserm), Françoise Boyer perrard(Centre Hospitalier Universitaire d'Angers), Isabelle Plo(Inserm), Claude Capron(Hôpital Ambroise-Paré), Marie‐Hélène Schlageter(Inserm)
Cited by 21
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777